Dr. Anil Koul, prior to taking the charge of Director, CSIR-IMTech, was Senior Director & Head, Respiratory Infections Discovery group at Johnson & Johnson based in Europe. Anil has more than 16 years of experience in pharmaceutical drug discovery and obtained his Ph.D. from Delhi University, Delhi and Max-Planck Institutein Germany. He attended a short residential program at Harvard Business School on innovation, strategy and leadership.
Dr Koul’s major achievement till date has been as a key scientist involved in discovery of Bedaquiline- the first drug for treatment of drug resistant TB discovered in last 45 years Bedaquline has been approved in US, Europe and several high TB burden countries like India, China and South Africa. In 2013, the World Health Organization (WHO) put Bedaquiline on list of its“ Essential Medicines”.
In 2017, Dr. Koul was confirmed with “Sun Pharma Science Foundation Award” by India’s Health Minister for his contribution to discovery of Bedaquiline. He was also awarded with Johnson Medal (2013), Swiss-TB Award (2005) etc for his seminal work in Bedaquiline. He has been invited to European Parliament to present to Europe-India Chamber of Commerce and has featured in Voice of America’s (VOI) radio news analysis around Bedaquiline drug-discovery.
Dr. Koul is a well-known and respected expert in pharmaceutical drug development with >35 peerreviewed publications more than 30 patents to this credit. He and his research teams have also discovered several new drug candidates for viral diseases and novel antibiotics.
He is a member of India’s Technical Advisory committee on Antimicrobial Resistance constituted by Ministry of Health and Family welfare, Govt. of India. He is also a member of Confederation of Indian Industry's (CII) Northern Region Committee on higher education.Dr. Koul is member of Board of directors for Technology business Incubators at KIIT and IISER universities. Dr. Koul is also a visiting professor at Faculty of Sciences at Free University of Amsterdam, Netherlands.
Atin Tomar is President of CPL Biologicals Pvt. Ltd., a joint venture company formed between Cadila Pharmaceuticals Limited, India and Novavax Inc, USA in 2009. CPL Biologicals focuses on research & development, manufacturing and commercialization of Vaccines, Biologics and Diagnostics for human health.
Atin brings with him comprehensive experience in the Biotechnology (Vaccines and Biologics) industry, globally. Atin’s experience and expertise spans from Process Development, Technology Transfer and Manufacturing Operations to Business Development, Licensing and Commercialization.
Prior to CPL Biologicals, Atin was associated with the Biotechnology industry in various roles. He was involved in the development of Biologics/Bio-therapeutics from the early stages of development to commercial manufacturing at Human Genome Sciences Inc., Amgen Inc. and Syngene International Limited (A Biocon Company). At Dr. Reddy’s Laboratories, MSD Wellcome Trust Hilleman Laboratories and International Vaccine Institute (IVI) Atin served in Business Development & Licensing, Program Management and Alliance (partnerships & collaborations) Management roles.
Atin completed his B.Tech (Hons) in Biotechnology and Biochemical Engineering from the Indian Institute of Technology (IIT) Kharagpur, India, MS in Biological Engineering from the University of Georgia, Athens, USA and Post-Graduate Programme in Management (MBA) in Finance and Strategy & Leadership from the Indian School of Business (ISB), Hyderabad, India.
Brief profile of Dr. Panchapagesa Murali P M Murali, is the Chairman of Jananom Private limited a young start up established in Bengaluru. He previously worked as the Managing Director of the Swiss International Company Evolva Biotech, one of the pioneering firms in biomolecular engineering in the world to generate products from microbial factories that are applied across diverse verticals from pharmaceuticals, nutraceuticals, flavours & fragrances, agriculture, veterinary, FMCG goods and defence. He was instrumental in establishing this as India's unique public private partnership model into a CSIR institute in Hyderabad before moving the establishment to Chennai. He was one of the first in the world to build a successful pipeline for pushing "molecules to market" to reap their commercial benefits, by building a rich ecosystem of contract research institutions and public research institutions not just in India but in several other countries as well. Many of these partnerships and collaborations were also anchored by Governments in Asia for welfare of the society. Some noteworthy examples include his work with Government of Singapore to build their synthetic biology ecosystem and in Malaysia to support producing a high value fragrance compound using fermentation thereby reducing deforestation. Many of these efforts had potentially saved tons of carbon footprint for the planet and in progressing towards achieving sustainable development goals for emerging economies. All these efforts led to winning the prestigious "company of the year" award globally.
Prior to Evolva, he founded & directed the R&D team at the Dalmia Centre for Research where he pioneered many herbal products and launched them successfully post all 4 phases of rigorous double-blind placebo controlled clinical trials. Thousands of patients and users benefited for many diseases affecting respiratory, cardiac, dental and cognitive systems.
Tobacco replacement, social forestry, expanding Neem's use were some of his noteworthy contributions. He won several awards & accolades for his services.
Dr. Mahesh Bhalgat is Executive Director – COO of Shantha Biotechnics. As head of Industrial Operations for Shantha, he has focused his efforts on regaining the WHO-pre qualification and initiating commercial supply of Shan5, Shantha’s pentavalent vaccine. Mahesh completed his B.Pharm from the University of Mumbai in India. Following his undergraduate education, Mahesh completed his Ph.D. in Medicinal Chemistry from the University of Utah. He has spent 20 years in the United States in the field of biotechnology and biologics before returning to India in 2009. While in the United States, Mahesh worked in many different areas of the biotechnology industry in the areas of R&D, Analytical & Process Development, Technology Transfer, Regulatory Sciences and Quality. Mahesh has experience dealing with the diversity seen in industry, working with both small and large companies in the United States such as Celera Genomics, Molecular Probes, Monsanto and Amgen. Within the biologics arena, Mahesh has worked on biotherapeutics, vaccines, agricultural biotechnology and research diagnostics. He has contributed to the submission of commercial and clinical product regulatory dossiers for biotherapeutics, achieved approvals for biotech crops and launched new research diagnostics tools. Following his return to India, Mahesh started working with Biological E Ltd. where he has contributed to the India and WHO approval of multiple vaccine products. Mahesh joined Shantha Biotech in 2013 and became a Board Member in 2015 and since then has been leading the transformation of vaccine industrial affairs.
Nachiket Mor has an MA and a PhD in Economics from the University of Pennsylvania; a Post-Graduate Diploma in Management from the Indian Institute of Management Ahmedabad; and a Bachelor of Science degree in Physics from the University of Bombay. He has interests in the fields of healthcare and financial services.
In healthcare, he was a member of the High-Level Expert Group on Universal Health Care, the Primary Care Task Force of the Ministry of Health and Family Welfare, the Health Commission for the State of Himachal Pradesh, and the Task Force on Global Health at the Academy of Medicine in Washington DC. He also helped create a new model for comprehensive primary care, pioneered by SughaVazhvu Healthcare in remote rural parts of Tamil Nadu. He currently serves as the India Country Director of the Bill & Melinda Gates Foundation.
In financial services, he has served on the Boards of RBI, ICICI, FIMMDA, IFMR Trust, CRISIL, NABARD, and MUDRA. While on the RBI Board he chaired the RBI Committee on Comprehensive Financial Services for Small Businesses and Low-Income Households, and the RBI Committee on the Licensing of Payment Banks.
Dr. Rajesh Jain is Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people.
Some of his key contributions are:
Dr. Shirshendu Mukherjee, trained as a Medical Microbiologist brings with him more than 2 decades of experience in academic institutes, Pharma companies and decade long experience in national, international philanthropic and Government funding agencies and has been instrumental in supporting the innovation ecosystem in the India and beyond.
Dr Mukherjee is currently the Mission Director of the Program Management Unit at BIRAC, formed by the partnership between the Bill & Melinda Gates Foundation, the Department of Biotechnology, Government of India and the Wellcome Trust which manages the Grand Challenges Program of the Foundation which funds a wide range of research areas from maternal and child health, infectious diseases, vaccines, point-of-care diagnostics, agricultural development, food and nutrition, sanitation and hygiene etc. that have direct or indirect impacts on health and development and also the Affordable Healthcare in India program of the Wellcome Trust, which funds translation research that could dramatically change the health and development landscape in India and beyond.
Dr. Mukherjee holds Ph.D. in Microbiology, Law graduate, Advance Course in Strategy Management form IIM Kolkata and Management and Leadership course form Said Business school University of Oxford.
Dr.Suresh Jadhav, M.Pharm., Ph.D. is the Executive Director of Serum Institute of India Pvt. Ltd. His 46 years technical expertise includes QC/QA/cGMP/GLP/GCP techniques, inspections of laboratories and validation of various production and quality control processes, pharma/toxicological screening of various drugs, toxins & venoms etc. & drugs pricing. He successfully led the project of development and introduction of Meningococcal A Conjugate Vaccine in Sub-Saharan African belt, the development of Seasonal & Pandemic Influenza Vaccines and also played major role in acquisition of Bilthoven Biologicals, The Netherlands. Being associated with DCVMN since its inception, Dr.Jadhav was its President for 5 years. He held the positions of GAVI Board / Alternate member as also member of GAVI PPC. He is also member on European Vaccine Initiative, FastVac, and Health Innovation in Practice Board etc. He is closely associated with various advisory committees e.g. Task Force of Sabin Vaccine Institute, WHO IVR-IVAC and Decades of Vaccines (DoV) etc.
Dr.Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc. He is the Chairman of Expert Committee on Vaccines and other Biologicals and also a member on the Scientific Body of Indian Pharmacopoeia Commission. He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, NVI/RIVM etc. and has published more than 100 technical papers in national & international journals, with extensive travel throughout the globe. He has to his credit two patents in his name. Ranked at 7th position amongst World’s 50 most influential people in Vaccines surveyed by Vaccinenation of Terrapinn. He is conferred with IPA Pune Lifetime Achievement Award 2015 by Indian Pharmaceutical Association.
Dr. Usha Barwale Zehr is Director and Chief Technology Officer at Maharashtra Hybrid Seeds Company Private Limited (MAHYCO), India. She received her Ph.D. from University of Illinois at Urbana-Champaign. Subsequent to her formal education, she worked at Purdue University in the Sorghum improvement program. For the last 20 years, she has been utilizing new technologies and tools including biotechnology for improving the quality and productivity of seeds and agriculture. In addition, Dr. Zehr serves as Director of Barwale Foundation (a non-profit Research Foundation). She also serves on the Board of the Donald Danforth Plant Science Center and Alliance for Green Revolution in Africa.
Dr. S. R. Rao, Senior Adviser, Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India is Ph.D in Mycology and Plant Pathology from Indian Agricultural Research Institute, New Delhi. He was visiting Scientist in Tottori University, Japan and at Waite Agricultural Experimental station, Adelaide Australia and has specialized in Molecular pathology. He served in various positions in Department of Biotechnology, Ministry of Science and Technology, Government of India since 1989 and was actively involved in several sophisticated biotech infrastructure facilities, research resources, forging bilateral collaboration with Asian and /European countries, introduction of Golden rice for research in India new beginning in veterinary biotechnology, biosecurity systems, formulation of National Biotech policies, strategic planning and investment matters. He served/serving as member of several Technical Committees of the Government of India; Academic /research councils of Universities/institutions. Currently, responsible for regulation of genetically engineering products as scientific Member Secretary of statutory body namely "Review Committee on Genetic Manipulation (RCGM)" operational for scientific risk assessment and management under Environmental Protection Act 1986 of India. He is also member of Genetic Engineering Appraisal Committee (GEAC) a statutory body for environmental release of Living Modified Organisms (LMOs) and Chairman of “Scientific Panel on GM Foods” of Food Safety Standards Authority of India (FSSAI) dealing with risk assessment of imported of GM Foods.
He specializes in core and cross-sectoral policy issues of Biotechnology policy, development, regulation, safety, biosecurity, public private partnership, international relations and biotech R&D Innovation and Development, and public concerns and consensus building; He is founder and editorial board member of Asian Biotechnology Development Review (ABDR) and has published more than 40 research papers in national/international Journals and made several presentations in various national and international conferences. The current areas of his work are formulating national policy and regulatory framework on bio-innovations through genome editing technology and reforms in agriculture, food and biopharma regulations & infrastructure.
Dr Arvind Kapur is a Ph.D. in Plant Biochemistry from Punjab Agricultural University Ludhiana and was Associate Professor in Plant Breeding for 8 years. In 1988, he joined private seed sector in a compan Proagro Seed as head Operations and R&D. As a Managing Director of Proagro- PGS a Joint ventures with leading Technology Company of Europe, promoted the “Seed Link” technology in Brassica to improve yield in oil crop. He became the Managing Director of Nunhems India, a leading subsidiary vegetable seed company of Netherland and led that company to become top company of vegetable seeds in India .He expanded the vegetable seed operation in Multi crops, Multi location research station in temperate and tropical vegetable crops. He also Headed the R and D of Asia Pacific of the company to established R and D centres in China, Indonesia etc.
In 2009 he started the Vegetable division of Rasi Seeds (P) Ltd under the brand “HyVeg” and become CEO of the vegetable seed operation.”HyVeg” is a known vegetable seed brand in INDIA.
He is now Managing director of the Company known as Acsen Hyveg pvt Ltd (Formerly Rasi seeds Pvt Ltd)
Dr Arvind Kapur has been secretary general and treasurer for National seed association of India (NSAI) for five years.
-He received Fellowship and merit certificate from distinguished science bodies in India for higher studies. Got certificate of merit for topping the list of successful candidates’ consecutives for three years. Citation offered for leading the group “Young Adventurous Club” for adventurous travel.
-Received award from the American Bibliographic Institute for the outstanding contribution to the farming communities in India.
-Received Bhartiya Udyog Ratan Award in 2006 and 2015 for his Individual Achievements and National Development from Indian Economic Development & Research Association (IEDRA).
Received recognition by Marquis” Who’s Who in the World” in 2013, 14, 15.
-Published 25 scientific articles and 25 general articles.
-Delivered more than 200 lectures on Biotechnologies, Policies, IPR and other agricultural related to wider audience in India and abroad.
-Chairman of the working group on IPR position paper to get it passed in AGMAPSA
-Member of IPC of ISF from Asia and presenting Asia's view on IPR.
-Co- chair of the FSII (Federation of Seed Industry of India )
Pranav Anam is one of the rare founder CEO's who have an innate ability to be able to flawlessly manage and deliver on multiple roles in business, cutting-edge technologies and being a specialist. He did his masters in Genetics from Newcastle University in and quickly climbed the ropes of the corporate ladder from being a Deputy GM to CEO below 30 years at Emprocell between 2011-2014. He played myriad roles at Emprocell from establishing the ethics board to defining operations strategy to establishing a dedicated institutional committee for Stem Cell Research and Therapy and attaining pivotal infrastructural and cooperative acquisition. Armed with this rich exposure and having been at the helm of various independent projects he set up The Gene Box in 2015. His passion for making a meaningful impact on an individual's wellness was the motivation to create an easy to use a product called The Gene Box. He invested 3 years in perfecting the algorithms that can deliver genetic reports from raw data. A person with infectious energy, passion and in-depth knowledge about Genetics and Stem cell research makes him a peoples person at The Gene Box which in turn helps him to effectively lead the teams across product development, engineering to business development and strategic alliances.
Pushpa leads the healthcare and lifesciences practice of Sathguru, a 30 year old consulting firm known for its expertise across strategy, corporate finance and innovation advisory. Sathguru has offices in Hyderabad and Boston and has a team of around 200 professionals across service offerings.
Pushpa is a sector expert and advises companies on emerging market growth strategies, M&A opportunities, portfolio optimization, innovation access and strategic partnerships. Engagements Pushpa has led in the pharma and biotech segment include segment strategies for leading pharma companies for biosimilars and peptides segments, pharma focused mid-term investment strategy for global PE fund with more than $1.5billion AUM in India, human vaccines segment strategy for a biotech company, policy advisory on preparedness for adoption of identified public health priorities and licensing transactions for phase III monoclonal antibodies for US market, microsphere drug delivery platform for peptide formulation and several 505(b)(2) assets. Pushpa converges sector depth and network with knowledge and experience across commercial considerations, regulatory requirements and IP implications to steer market entry and accelerate growth. Pushpa has also been part of critical policy advisory efforts at the national and international level.
Pushpa’s prior experience of about fourteen years includes leading consulting engagements in PwC and E&Y and technology transfer experience at the University of Michigan Technology Transfer Office. She has a bachelor’s degree from Osmania University (India), an MBA from the Ross School of Business at University of Michigan and is a member of the Institute of Chartered Accountants of India. Pushpa serves as an alumni advisor to the India Business Conference at the University of Michigan, is a mentor to ventures on the MassConnect (Massachusetts, USA) program and is the primary grantee of a Grand Challenges Canada program to develop a vaccine carrier suitable for the Indian context.
Dr. Ramanan Thirumoorthy is Vice President - Technical at Richcore Lifesciences Pvt. Ltd, Bangalore. He has over 20 years of experience in recombinant protein biotechnology, including protein purification, structure elucidation and analytical chemistry. He started as a chemistry graduate with a masters from IIT, Madras followed by PhD in Biochemistry from University of Florida, USA. After 3 years of postdoctoral experience in the US and Canada, he moved back to India to start his R&D career in pharmaceutical industry. He has over 15 patents and publications. He currently heads the R&D at Richcore, which is involved in the development of clones and fermentation process to produce recombinant proteins for biopharma applications.
Prof. Samir K. Brahmachari is the Academy Professor of Academy of Scientific and Innovative Research, and Chief Mentor of Open Source Drug Discovery. He is also the Chief Mentor, Health Technology Innovations for ACCESS Health International, Inc. He is the Founder Director of CSIR – Institute of Genomics and Integrative Biology (1997-2007) and former Director General of CSIR and Secretary, DSIR, Government of India (2007-2013). He conceptualized and implemented the functional genomics research in India and the Indian Genome Variation Project. He presently mentors several startups in Genomic Medicine and Big data analytics.
He is the recipient of many national and international awards including Shanti Swarup Bhatnagar prize. He is an elected fellow of The World Academy of Sciences, the European Society of Preventive Medicine and member of all four National Academies of Science & Engineering, India.
Quality and compliance professional with three decades of experience in biologics and biosimilars industry. Have worked in R&D, Manufacturing and Quality domains in various leading Vaccine and Biopharmaceutical companies in India.
My expertise is in establishing global quality systems, quality analytics, troubleshooting and building quality culture in organizations.
Experienced in technology and facility evaluations, technology transfers, regulatory audits, CMC reviews, GLP and GMP Trainings and Risk Assessments.
Kapil has three decades of leadership experience. He first built his career in the technology industry and was leading Sun Microsystems and then Tektronix in India. He got inspired by the Mission of Thermo Fisher (Enable our customers to make the world healthier, cleaner and safer) and how he could get the opportunity of impacting the lives of people in true sense. He now manages the business of Life Sciences Solutions Group for South Asia at Thermo Fisher and also leads all the global teams based out of Bangalore.
Kapil has a bachelor’s degree in engineering. He is also a Fulbright Fellow and completed ‘Leadership in Management’ program from Carnegie Mellon University.
Mr. Neeraj Gupta, has been in the life sciences and molecular diagnostics business since last 2 decades at ILS with a mission to provide latest, advanced state-of-the-art global technologies to the Indian scientific fraternity for research in Genomics, Cell biology, Molecular Imaging and Advanced Molecular Diagnostics. The ILS Research and development program develops cost effective and highly sensitive molecular test for Indian population with the advanced technologies previously unknown to the Indian market. Some of these tests are now being recommended by Indian government for National Population screening program on Thalassemia and sickle cell anemia.
Mr. Gupta also is the Founder & CEO of Genes2Me LLP, a personalized medicine and molecular diagnostics startup, with focus of bringing advanced Molecular diagnostic technologies for the Indian clinicians and bridging the Gap in the Advanced Molecular Diagnostics market. He runs the organization with the belief of creating a benchmark in the field of personalized healthcare particularly in the areas of Mother & Child, Oncology, Preventive Wellness & Genetic screening and provide advanced molecular diagnostic testing at an affordable pricing. Genes2me aims to introduce a large Pharmacogenomics (PGX) screening program on Indian population for the genetic predisposition for various drugs, their effects and validation, in health conditions and lifestyle disorders. Mr. Gupta aims to bring a meaningful change in the current molecular genetics, diagnostics & personalized medicine market in the Indian subcontinent.
Dr. Paresh Verma is currently working as President, South East Asia and Director Research in Shriram Bioseed Genetics. Prior to joining Bioseed, he has worked in Proagro Seed Company (now Bayer Bio Science), University of Nebraska and the International Crops Research Institute for Semi Arid Tropics (ICRISAT). Dr. Verma holds post graduate degrees from GB Pant University of Agriculture & Technology and the University of Nebraska.
Dr. Liu Muyun, Director of the National and Local Joint Engineering Laboratory of Personalized Cell Therapy, Founder of the Shenzhen Kenuo Medical Laboratory.
As a member of China National Medicine Policy Expert Committee of Xinhua Liaowang Think-tank, From 2015 to 2018, Dr. Liu made constructive suggestions on health and sustainable development in the field of cell therapy at the National People's Congress (NPC) as well as the National Committee of the Chinese People's Political Consultative Conference (CPPCC). Being an expert in industrial policy research, she was invited to design Strategic Emerging Industries and outline of mid-long development program for future industry by Shenzhen municipal government.As one of the founder members, Dr. Liu co-founded the Chinese Journal of Cell and Stem Cell.
Dr Anurag Agrawal is Director of the CSIR Institute of the Genomics and Integrative Biology. He graduated in medicine from the All India Institute of Medical Sciences in 1994, followed by specialization in Internal Medicine, Pulmonary Disease, and Critical Care from Baylor College of Medicine, Houston, (2003) and a PhD in physiology from Delhi University. After serving as a faculty member of the Department of Medicine at Baylor, he joined CSIR-IGIB in 2007, where he established the Centre of Excellence for Translational Research in Asthma & Lung disease (TRiAL) and the CSIR program for Effective Application of Community Health efforts through new age Information Technology (EACH-IT). His research activities include use of experimental and computational model-systems to study disease, especially asthma. Dr Agrawal believes health data analytics, with artificial intelligence applications, to be the new frontier of medicine and is actively engaged in promoting the confluence of medicine and informatics. He has more than 100 scientific publications, mostly original research findings communicated in high-impact journals. He has been recognized internationally, as an alumnus of Kavli Frontiers of Science program of the US National Academy of Sciences. His work as been recognized in the form of the Shanti Swaroop Bhatnagar award (Medical Sciences, 2014), National Bioscience award (2015), Wellcome Trust DBT India Alliance senior fellowship (2015), Lady Tata Young Researcher Award (2010) and the Swarnjayanti Fellowship of the Department of Science and Technology (2010). Dr. Agrawal is a member and fellow of numerous academic societies and serves on advisory bodies at Public Health Foundation of India, Lady Tata Memorial Trust, Centre for Cellular & Molecular Biology, Centre for Brain Research, and Indraprastha Institute of Information Technology, amongst others, as well as an advisor for start up companies and healthcare organizations.
Dr. Venkata Ravi Kumar Banda has pioneered innovations in molecular diagnostics for over 23 years. An outstanding practicing physician, Dr. Ravi Kumar’s long career also comprises world- class research and development: in institutions, large multinational corporations and in multiple startups.
In 1978, Dr. Ravi Kumar graduated with an MBBS from the renowned Jawaharlal Institute of Post- Graduate Medical Education and Research (JIPMER), in Pondicherry, India. He was awarded as the best House Surgeon that year. Prior to completing a PhD in Neurochemistry at the prestigious Indian Institute of Science, Bangalore, he also served as Registrar in Psychiatry at the Christian Medical College in Vellore. His PhD thesis won the Prof. Giri Memorial Gold Medal for Best Thesis from the Indian Institute of Science in 1985.
Dr. Ravi Kumar then worked as a senior scientist and Group Leader at the Astra Research Centre India. The teams he led worked with Nobel Laureates from Sweden and focused on several important tropical diseases. During his 7 years there, he filed several patents and carried out groundbreaking research in parasitic infections and neurocysticercosis. Dr. Ravi Kumar also found time to guide students to their PhDs at two different institutions while being a full-time researcher and physician.
In 1994, Dr. Ravi Kumar founded XCyton Diagnostics Private Limited. He has since stewarded the company to remarkable success in the field of immunodiagnostics and molecular diagnostics. Under his leadership, XCyton has won numerous awards:
From 2005, Dr. Ravi Kumar and his team of researchers began developing syndrome-based molecular diagnostic (SES) panels, and successfully established over 20 panels by 2011. His singular achievement has been the development of this proprietary platform for infectious diseases, which is capable of ruling out or confirming every known pathogen for all the important clinical infectious syndromes seen by intensivists. In a critical care setting, these panels have saved thousands of lives by their sensitivity and accuracy.
Dr. Ravi Kumar has spoken and presented at numerous international conferences and symposia, and published his research work in highimpact scientific journals. He has been educating clinicians and researchers in infectious disease, syndrome evaluation and evidencebased medicine for nearly two decades now. He continues to support clinical studies in this area in partnership with the National University Hospital in Singapore, and Harvard University (Brigham and Women’s Hospital) in the USA.
Dr. Ravi Kumar’s experience and innovations make him a unique leader in caring for critically ill patients. His work has transformed our understanding of infectious disease, ensured effective clinical and therapeutic practices in critical illness, and created the world’s most powerful toolkit to battle the global crisis of antimicrobial resistance.
Dr. Davinder Gill has served as the Chief Executive Officer at Hilleman Laboratories since 2012. Dr. Gill comes with two decades of R&D and business experience in Global Pharma and Biotech companies. At Hilleman Labs, Dr. Gill is responsible for Company Strategy, Product Development, Fund Raising and Public Affairs.
Dr. Gill started his career in 1998 at Millennium Pharmaceuticals in Cambridge, Massachusetts in the area of Biotherapeutics. In 2003, he moved to Wyeth, Collegeville, Pennsylvania where he served in roles of increasing responsibility as Vice President of Biological Technologies. At Wyeth, Dr. Gill was instrumental in creating and leading first-of-their-kind R&D Laboratories in Ireland and Scotland in collaboration with local governments. After the acquisition of Wyeth in 2009, Dr. Gill served as Vice President and Head, Global Biotherapeutics at Pfizer, New York where he successfully led an international team and was a member of Pfizer CEO Council. In 2012, Dr. Gill was appointed CEO at Hilleman Laboratories.
Dr. Gill holds a Ph.D in Chemical Engineering from University of Houston, Texas and is an alumnus of the Indian Institute of Technology. He completed a Cancer Research Institute (New York) Fellowship at the Massachusetts General Hospital/Harvard Medical School in Boston, Massachusetts.
Hospital/Harvard Medical School in Boston, Massachusetts. In addition to his role as CEO at Hilleman Labs, Dr. Gill is also a member of The Wellcome Trust (London, UK) Affordable Healthcare Initiative as well as the National Committee on Public Health, Confederation of Indian Industry (New Delhi, India).
Dr. Gill is the founder of a private charity, Amkar Trust.
Deepak Pental has been a Professor of Genetics at the University of Delhi South Campus till 2016. From 2005-10 he served as the Vice-chancellor of University of Delhi. His research interests are in breeding of oilseed mustard and cotton using both conventional and genetic engineering technologies. His group has published 94 research papers in peer reviewed journals and received a number of national and international patents. He is an elected member of the National Academy of Agricultural Sciences, the National Academy of Sciences, the Indian Academy of Sciences and the Indian National Science Academy and recipient of many awards which include – Om Prakash Bhasin Award in 2008, FICCI award in 2010, D.Sc (hc) from the University of Nottingham in 2012, J. C. Bose Fellowship of DST in 2009 and ‘Life Time Achievement Award in Agriculture’ by Mahindra and Mahindra foundation in 2018. He is currently a CSIR-Distinguished Scientist.